KRAS Mutation Analysis (Extended) in Colorectal Cancer (CRC)
Use
KRAS is a guanosine triphosphate (GTP) binding protein involved in downstream receptor signaling, which is critical for cell proliferation, survival, and differentiation. Mutations in the KRAS oncogene are frequently found in human cancers, including colorectal cancer (CRC). This assay detects KRAS mutations in exons 2, 3, and 4, enabling determination of drug response.
Special Instructions
Provide a copy of the pathology report; the KRAS test will be delayed if the pathology report is not received. Direct any questions regarding this test to customer service at 800-345-4363.
Limitations
This assay is able to detect 5% mutation in a background of wild‑type DNA. This test was developed, and its performance characteristics determined, by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA).
Methodology
PCR-based (PCR)
Biomarkers
Result Turnaround Time
5-7 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Formalin‑fixed, paraffin‑embedded (FFPE) tissue block or four unstained slides and one matching H&E‑stained slide at 5 µM
Minimum Volume
Two unstained slides and one matching H&E‑stained slide at 5 μM; samples with >4 mm² and ≥50% tumor content preferred
Container
FFPE tissue blocks or slides
Storage Instructions
Maintain blocks and slides at room temperature
Causes for Rejection
Tumor block containing no tumor tissue; broken or stained slides
Other tests from different labs that may be relevant